2 Information about guselkumab

Marketing authorisation indication

2.1 Guselkumab (Tremfya, Janssen), 'alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The cost of a 100‑mg pre-filled disposable injection of guselkumab is £2,250.00 (excluding VAT; BNF online, accessed February 2021). The company has a commercial arrangement. This makes guselkumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)